Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma

Sean Christopher Dowdy, Ralitsa T. Loewen, Giovanni Aletti, Simone S. Feitoza, William Arthur Cliby

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objective: To describe the technique of diaphragmatic peritonectomy (DP) for ovarian cancer cytoreduction and to assess associated morbidity. Methods: Retrospective review yielded 56 patients who underwent DP as part of a cytoreductive procedure for primary or recurrent ovarian cancer between 1988 and 2004. Patients who underwent diaphragmatic resection, removal of diaphragmatic implants with CUSA, cautery, curette, or finger fracture, and patients with pseudomyxoma were excluded from analysis. Results: DP was performed as a component of primary or secondary cytoreduction in 37 (66%) and 19 (34%) patients, respectively. Extended procedures including bowel resection, hepatic resection, splenectomy, or radical hysterectomy were performed with DP in 47 patients (82%). Resection of all disease > 1 cm was achieved in 95% (microscopic residuum in 43%). For those undergoing primary cytoreduction, median survival was 59 months and 5-year survival was 49% with median follow-up of 34 months. When performed for recurrent ovarian carcinoma, 5-year survival was 16% and median survival was 23 months. No intra-operative complications could be specifically attributed to DP. Post-operative complications included a 30% rate of pleural effusion which was associated with entry into the pleural space during DP (p < 0.0001); thoracentesis was required in 12.5%. Conclusions: Diaphragmatic metastases are a common obstacle to optimal cytoreduction for patients with ovarian cancer. When necessary, utilizing DP in concert with other extended procedures to obtain maximal cytoreduction is associated with excellent survival. It should be recognized that DP is associated with an increased incidence of post-operative pleural effusion, particularly when the pleural space is entered.

Original languageEnglish (US)
Pages (from-to)303-307
Number of pages5
JournalGynecologic Oncology
Volume109
Issue number2
DOIs
StatePublished - May 2008

Fingerprint

Outcome Assessment (Health Care)
Morbidity
Carcinoma
Survival
Ovarian Neoplasms
Pleural Effusion
Cautery
Splenectomy
Hysterectomy
Fingers
Neoplasm Metastasis
Liver
Incidence

Keywords

  • Cytoreductive surgery
  • Diaphragm
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. / Dowdy, Sean Christopher; Loewen, Ralitsa T.; Aletti, Giovanni; Feitoza, Simone S.; Cliby, William Arthur.

In: Gynecologic Oncology, Vol. 109, No. 2, 05.2008, p. 303-307.

Research output: Contribution to journalArticle

@article{ccaa6457599f412ea3568fbe78e1069d,
title = "Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma",
abstract = "Objective: To describe the technique of diaphragmatic peritonectomy (DP) for ovarian cancer cytoreduction and to assess associated morbidity. Methods: Retrospective review yielded 56 patients who underwent DP as part of a cytoreductive procedure for primary or recurrent ovarian cancer between 1988 and 2004. Patients who underwent diaphragmatic resection, removal of diaphragmatic implants with CUSA, cautery, curette, or finger fracture, and patients with pseudomyxoma were excluded from analysis. Results: DP was performed as a component of primary or secondary cytoreduction in 37 (66{\%}) and 19 (34{\%}) patients, respectively. Extended procedures including bowel resection, hepatic resection, splenectomy, or radical hysterectomy were performed with DP in 47 patients (82{\%}). Resection of all disease > 1 cm was achieved in 95{\%} (microscopic residuum in 43{\%}). For those undergoing primary cytoreduction, median survival was 59 months and 5-year survival was 49{\%} with median follow-up of 34 months. When performed for recurrent ovarian carcinoma, 5-year survival was 16{\%} and median survival was 23 months. No intra-operative complications could be specifically attributed to DP. Post-operative complications included a 30{\%} rate of pleural effusion which was associated with entry into the pleural space during DP (p < 0.0001); thoracentesis was required in 12.5{\%}. Conclusions: Diaphragmatic metastases are a common obstacle to optimal cytoreduction for patients with ovarian cancer. When necessary, utilizing DP in concert with other extended procedures to obtain maximal cytoreduction is associated with excellent survival. It should be recognized that DP is associated with an increased incidence of post-operative pleural effusion, particularly when the pleural space is entered.",
keywords = "Cytoreductive surgery, Diaphragm, Ovarian carcinoma",
author = "Dowdy, {Sean Christopher} and Loewen, {Ralitsa T.} and Giovanni Aletti and Feitoza, {Simone S.} and Cliby, {William Arthur}",
year = "2008",
month = "5",
doi = "10.1016/j.ygyno.2008.02.012",
language = "English (US)",
volume = "109",
pages = "303--307",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma

AU - Dowdy, Sean Christopher

AU - Loewen, Ralitsa T.

AU - Aletti, Giovanni

AU - Feitoza, Simone S.

AU - Cliby, William Arthur

PY - 2008/5

Y1 - 2008/5

N2 - Objective: To describe the technique of diaphragmatic peritonectomy (DP) for ovarian cancer cytoreduction and to assess associated morbidity. Methods: Retrospective review yielded 56 patients who underwent DP as part of a cytoreductive procedure for primary or recurrent ovarian cancer between 1988 and 2004. Patients who underwent diaphragmatic resection, removal of diaphragmatic implants with CUSA, cautery, curette, or finger fracture, and patients with pseudomyxoma were excluded from analysis. Results: DP was performed as a component of primary or secondary cytoreduction in 37 (66%) and 19 (34%) patients, respectively. Extended procedures including bowel resection, hepatic resection, splenectomy, or radical hysterectomy were performed with DP in 47 patients (82%). Resection of all disease > 1 cm was achieved in 95% (microscopic residuum in 43%). For those undergoing primary cytoreduction, median survival was 59 months and 5-year survival was 49% with median follow-up of 34 months. When performed for recurrent ovarian carcinoma, 5-year survival was 16% and median survival was 23 months. No intra-operative complications could be specifically attributed to DP. Post-operative complications included a 30% rate of pleural effusion which was associated with entry into the pleural space during DP (p < 0.0001); thoracentesis was required in 12.5%. Conclusions: Diaphragmatic metastases are a common obstacle to optimal cytoreduction for patients with ovarian cancer. When necessary, utilizing DP in concert with other extended procedures to obtain maximal cytoreduction is associated with excellent survival. It should be recognized that DP is associated with an increased incidence of post-operative pleural effusion, particularly when the pleural space is entered.

AB - Objective: To describe the technique of diaphragmatic peritonectomy (DP) for ovarian cancer cytoreduction and to assess associated morbidity. Methods: Retrospective review yielded 56 patients who underwent DP as part of a cytoreductive procedure for primary or recurrent ovarian cancer between 1988 and 2004. Patients who underwent diaphragmatic resection, removal of diaphragmatic implants with CUSA, cautery, curette, or finger fracture, and patients with pseudomyxoma were excluded from analysis. Results: DP was performed as a component of primary or secondary cytoreduction in 37 (66%) and 19 (34%) patients, respectively. Extended procedures including bowel resection, hepatic resection, splenectomy, or radical hysterectomy were performed with DP in 47 patients (82%). Resection of all disease > 1 cm was achieved in 95% (microscopic residuum in 43%). For those undergoing primary cytoreduction, median survival was 59 months and 5-year survival was 49% with median follow-up of 34 months. When performed for recurrent ovarian carcinoma, 5-year survival was 16% and median survival was 23 months. No intra-operative complications could be specifically attributed to DP. Post-operative complications included a 30% rate of pleural effusion which was associated with entry into the pleural space during DP (p < 0.0001); thoracentesis was required in 12.5%. Conclusions: Diaphragmatic metastases are a common obstacle to optimal cytoreduction for patients with ovarian cancer. When necessary, utilizing DP in concert with other extended procedures to obtain maximal cytoreduction is associated with excellent survival. It should be recognized that DP is associated with an increased incidence of post-operative pleural effusion, particularly when the pleural space is entered.

KW - Cytoreductive surgery

KW - Diaphragm

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=42749093591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749093591&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.02.012

DO - 10.1016/j.ygyno.2008.02.012

M3 - Article

C2 - 18384866

AN - SCOPUS:42749093591

VL - 109

SP - 303

EP - 307

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -